The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.
The new edition (BNF 82) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.
Extensive content updates in the BNF 82 edition include:
New monographs for:
- COVID-19 vaccine for active immunisation against COVID-19 disease
- Enhertu® [trastuzumab deruxtecan] for HER2-positive unresectable or metastatic breast cancer
- Myalepta® [metreleptin] for leptin deficiency in lipodystrophy
- Phesgo® [pertuzumab with trastuzumab] for HER2-positive early-stage, metastatic, or locally recurrent breast cancer
- Treprostinil for idiopathic or hereditary pulmonary arterial hypertension
- Trixeo Aerosphere® [formoterol fumarate with glycopyrronium and budesonide] and Bevespi Aerosphere® [glycopyrronium with formoterol fumarate] for chronic obstructive pulmonary disease
- Von Willebrand Factor for von Willebrand disease
MHRA advice on:
- Aminoglycosides: increased risk of deafness in patients with mitochondrial mutations
- Dimethyl fumarate (Tecfidera®): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
- Epilepsy: updated advice on antiepileptic drugs in pregnancy following comprehensive safety review
- Erythromycin: caution required due to cardiac risks (QT interval prolongation) and drug interaction with rivaroxaban
- Fingolimod (Gilenya®): updated advice about the risks of serious liver injury and herpes meningoencephalitis
- Hydrocortisone (Alkindi®): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules
- Medicines in pregnancy and breastfeeding: new initiative for consistent guidance and report on optimising data for medicines used during pregnancy
- Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect when mixed, leading to an increased risk of aspiration
- Tofacitinib (Xeljanz®▼): initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF-alpha inhibitors
- Ulipristal acetate 5mg (Esmya®): further restrictions due to risk of serious liver injury
- SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
Other significant changes include updated guidance on:
- COVID-19, including immunisation and recommendations on choice of COVID-19 vaccine in-line with Joint Committee on Vaccination and Immunisation and Public Health England recommendations
- Management of hypoglycaemia, including age-based dose banding
- Management of polycystic ovary syndrome
- National flu immunisation programme and influenza vaccine in-line with Public Health England recommendations
- Progestogen-only contraceptives in-line with Faculty of Sexual & Reproductive Healthcare recommendations
- Treatment of human and animal bites
- Use of hepatitis B immunoglobulin and vaccines in-line with Public Health England recommendations
BNF 82 is an essential publication, it provides you with:
- Up-to-date information on prescribing, dispensing, and administering medicines
- Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
- Information you know you can trust for quality, reliability, and independence
- Everything you need at your fingertips, all in one book
مراجعة واحدة لـ BNF 82 (British National Formulary)
لا توجد مراجعات بعد.